Zymeworks Inc
NYSE:ZYME
Zymeworks Inc
Cash from Financing Activities
Zymeworks Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Zymeworks Inc
NYSE:ZYME
|
Cash from Financing Activities
$81.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Financing Activities
$842k
|
CAGR 3-Years
-85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cash from Financing Activities
$142m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Financing Activities
-$5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Financing Activities
CA$5.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
Sunshine Biopharma Inc
OTC:SBFM
|
Cash from Financing Activities
$3.4m
|
CAGR 3-Years
29%
|
CAGR 5-Years
45%
|
CAGR 10-Years
22%
|
See Also
What is Zymeworks Inc's Cash from Financing Activities?
Cash from Financing Activities
81.8m
USD
Based on the financial report for Dec 31, 2023, Zymeworks Inc's Cash from Financing Activities amounts to 81.8m USD.
What is Zymeworks Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-2%
Over the last year, the Cash from Financing Activities growth was -25%. The average annual Cash from Financing Activities growth rates for Zymeworks Inc have been -36% over the past three years , -2% over the past five years .